Literature DB >> 1993635

Tumor and treatment factors improving outcome in stage III-B cervix cancer.

R M Lanciano1, K Martz, L R Coia, G E Hanks.   

Abstract

This report reviews 271 patients with Stage III-B squamous cell cancer of the uterine cervix from three national surveys conducted by the Patterns of Care Study. A progressive increase in local control and survival is seen among the three surveys which parallels a progressive increase in paracentral (point A) dose and use of intracavitary treatment. Multivariate analysis reveals extent of pelvic disease (unilateral sidewall vs. bilateral sidewall vs. lower 1/3 vagina) and use of intracavitary treatment to be the only significant tumor and treatment factors associated with local control and survival. With aggressive radiotherapy, local control rates exceeding 65% and survival of 50% at 4 years can be anticipated at the expense of a small increase in complications.

Entities:  

Mesh:

Year:  1991        PMID: 1993635     DOI: 10.1016/0360-3016(91)90143-r

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Current status and perspectives of brachytherapy for cervical cancer.

Authors:  Takafumi Toita
Journal:  Int J Clin Oncol       Date:  2009-02-20       Impact factor: 3.402

2.  Comparison of efficacy of meperidine and fentanyl in terms of pain management and quality of life in patients with cervical cancer receiving intracavitary brachytherapy: a double-blind, randomized controlled trial.

Authors:  Saengrawee Thanthong; Sirikorn Rojthamarat; Wipra Worasawate; Phongthara Vichitvejpaisal; Danupon Nantajit; Nantakarn Ieumwananontachai
Journal:  Support Care Cancer       Date:  2017-03-18       Impact factor: 3.603

Review 3.  Brachytherapy in Gynecologic Cancers: Why Is It Underused?

Authors:  Kathy Han; Akila N Viswanathan
Journal:  Curr Oncol Rep       Date:  2016-04       Impact factor: 5.075

4.  Intensity-modulated arc therapy with simultaneous integrated boost in the treatment of primary irresectable cervical cancer. Treatment planning, quality control, and clinical implementation.

Authors:  Katrien Vandecasteele; Wilfried De Neve; Werner De Gersem; Louke Delrue; Leen Paelinck; Amin Makar; Valérie Fonteyne; Carlos De Wagter; Geert Villeirs; Gert De Meerleer
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

5.  Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer.

Authors:  Akila N Viswanathan; Beth Erickson; David K Gaffney; Sushil Beriwal; Sudershan K Bhatia; Omer Lee Burnett; David P D'Souza; Nikhilesh Patil; Michael G Haddock; Anuja Jhingran; Ellen L Jones; Charles A Kunos; Larissa J Lee; Lilie L Lin; Nina A Mayr; Ivy Petersen; Primoz Petric; Lorraine Portelance; William Small; Jonathan B Strauss; Kanokpis Townamchai; Aaron H Wolfson; Catheryn M Yashar; Walter Bosch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-01       Impact factor: 7.038

6.  Contribution of pelvic and para-aortic lymphadenectomy with sentinel node biopsy in patients with IB2-IIB cervical cancer.

Authors:  E Chéreau; J-G Feron; M Ballester; C Coutant; C Bezu; R Rouzier; E Touboul; E Daraï
Journal:  Br J Cancer       Date:  2011-12-06       Impact factor: 7.640

7.  The usefulness of an independent patient-specific treatment planning verification method using a benchmark plan in high-dose-rate intracavitary brachytherapy for carcinoma of the uterine cervix.

Authors:  Yutaka Takahashi; Masahiko Koizumi; Iori Sumida; Fumiaki Isohashi; Toshiyuki Ogata; Yuichi Akino; Yasuo Yoshioka; Shintaro Maruoka; Shinichi Inoue; Koji Konishi; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2012-07-17       Impact factor: 2.724

8.  Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer.

Authors:  Yuuki Kuroda; Naoya Murakami; Madoka Morota; Shuhei Sekii; Kana Takahashi; Koji Inaba; Hiroshi Mayahara; Yoshinori Ito; Ryo-Ichi Yoshimura; Minako Sumi; Yoshikazu Kagami; Noriyuki Katsumata; Takahiro Kasamatsu; Jun Itami
Journal:  J Radiat Res       Date:  2012-06-15       Impact factor: 2.724

9.  Optimizing parametrial aperture design utilizing HDR brachytherapy isodose distribution.

Authors:  Katherine L Chapman; Nitin Ohri; Timothy N Showalter; Laura A Doyle
Journal:  J Contemp Brachytherapy       Date:  2013-03-29

10.  Stereotactic body radiation therapy via helical tomotherapy to replace brachytherapy for brachytherapy-unsuitable cervical cancer patients - a preliminary result.

Authors:  Chen-Hsi Hsieh; Hui-Ju Tien; Sheng-Mou Hsiao; Ming-Chow Wei; Wen-Yih Wu; Hsu-Dong Sun; Li-Ying Wang; Yen-Ping Hsieh; Yu-Jen Chen; Pei-Wei Shueng
Journal:  Onco Targets Ther       Date:  2013-02-04       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.